Results 71 to 80 of about 392,226 (299)

Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30 [PDF]

, 2019
BACKGROUND: The benefits of chemotherapy in node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with the 21-gene recurrence score (RS) of 18-30, particularly those with RS 26-30 ...
Cho, Young Up, Colditz, Graham A, Han, Yunan, Kim, Seung Il, Liu, Ying, Park, Byeong-Woo, Park, Seho, Park, Yikyung, Peterson, Lindsay L, Toriola, Adetunji T   +9 more
core   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma [PDF]

, 2016
BACKGROUND: This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III).
ANTONELLI, MANILA, Balter, Rita, Barra, Salvina, Bertin, Daniele, Bertolini, Patrizia, Biassoni, Veronica, Boschetti, Luna, Buccoliero, Annamaria, BUTTARELLI, Francesca Romana, Calareso, Giuseppina, Cama, Armando, Cinalli, Giuseppe, Diletto, Barbara, Ferroli, Paolo, Gandola, Lorenza, Garrè, Maria Luisa, Genitori, Lorenzo, GIANGASPERO, FELICE, Giombelli, Ermanno, Giussani, Carlo, La Spina, Milena, Marras, Carlo Efisio, Mascarin, Maurizio, Massimino, Maura, MASTRONUZZI, ANGELA, Miceli, Rosalba, Modena, Piergiorgio, Mussano, Anna, Pecori, Emilia, Peretta, Paola, Pollo, Bianca, Quaglietta, Lucia, Sardi, Iacopo, Scarzello, Giovanni, Schiavello, Elisabetta, Scoccianti, Silvia, Valentini, Laura, Viscardi, Elisabetta   +37 more
core   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study

Lipids in Health and Disease, 2021
Background Cancer patients often exhibit chemotherapy-associated changes in serum lipid profiles, however, their prognostic value before and after adjuvant chemotherapy on survival among non-small-cell lung cancer (NSCLC) patients is unknown.
Fan Luo, Kang-mei Zeng, Jia-xin Cao, Ting Zhou, Su-xia Lin, Wen-juan Ma, Yun-peng Yang, Zhong-han Zhang, Fei-teng Lu, Yan Huang, Hong-yun Zhao, Li Zhang   +11 more
doaj   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch, A Hurtado, A Noske, AA Lazar, AC Wolff, Andre Robidoux, BM Müller, Bruno V Sinn, C Denkert, Carsten Denkert, Christine Solbach, CK Osborne, D Slamon, DG Altman, DJ Dabbs, EA Perez, EH Romond, FL Baehner, G Hennig, G Konecny, G Pentheroudakis, G von Minckwitz, G von Minckwitz, G von Minckwitz, Gunter von Minckwitz, H Joensuu, Hans Tesch, I Pinhel, J Baselga, J Baselga, Jan C Brase, Jens Huober, Judith Prinzler, K Bohmann, Keyur Mehta, Knut Engels, L Gianni, L Gianni, LM McShane, M Bonetti, M Dowsett, M Dowsett, M Filipits, M Untch, M Untch, M Untch, M Untch, Martin-Leo Hansmann, Mattea Reinisch, ME Hammond, Michael Untch, MJ Piccart-Gebhart, MP Fereshteh, PC Roche, Peter A Fasching, Ralf Kronenwett, S Johnston, S Paik, S Paik, Sibylle Loibl, Silvia Darb-Esfahani, T Lahusen, W Zhao   +62 more
core   +1 more source

Fetal Brain Tumor Harboring a Unique ROCK1::BRAF Fusion

Pediatric Blood &Cancer, EarlyView.
Marllon Cindra Sant'Ana, Mariana Maschietto, Daniela Paz Leal, Ricardo de Santos de Oliveira, Mayara Ferreira Euzébio, Antonio Carlos dos Santos, Luciano Neder, Carlos Alberto Scrideli, Elvis Terci Valera   +8 more
wiley   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy

The Saudi Journal of Gastroenterology, 2012
Background/Aim: Adjuvant chemotherapy for 6 months is the current standard of care after potentially curative resection of pancreatic cancer and yields an overall survival of 15-20 months. Early tumor recurrence before or during adjuvant chemotherapy has
Richard Fischer, Matthias Breidert, Tobias Keck, Frank Makowiec, Christian Lohrmann, Jan Harder   +5 more
doaj   +1 more source

A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. [PDF]

, 2015
BACKGROUND: The relationship between chemotherapy-related toxicities and prognosis is unclear. Previous studies have examined the association of myelosuppression parameters or neuropathy with survival and reported conflicting results.

core   +2 more sources